Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
GLP-1 receptor agonists, best known as diabetes and weight-loss drugs, may have a surprising new benefit: helping ulcerative colitis patients achieve remission. A matched cohort study found that UC patients on GLP-1RAs were nearly six times more likely to reach symptomatic remission at 12 weeks compared to those not on the drugs. Semaglutide edged out liraglutide in effectiveness, and the benefits appeared as early as week 4.
GLP-1 receptor agonists (GLP-1RAs) — the class of drugs that includes semaglutide (Ozempic/Wegovy) and liraglutide — are already celebrated for managing diabetes and obesity. Now, a new real-world study suggests they may also help patients with ulcerative colitis (UC) achieve remission, thanks to their anti-inflammatory and gut-healing properties.
Researchers at West Virginia University retrospectively analyzed 300 UC patients (150 GLP-1RA users, 150 matched controls) and found that those on GLP-1RAs were dramatically more likely to reach symptomatic remission at 12 weeks. The benefits kicked in early — as soon as week 4 — and were not linked to weight loss, suggesting the drugs' anti-inflammatory mechanisms are driving the effect. Importantly, GLP-1RA use was not associated with increased UC flare-ups or hospitalizations.
By the Numbers:
Why it matters: These findings open the door to GLP-1RAs as a potential adjunctive therapy for UC — a condition that affects millions and can be difficult to manage. While prospective trials are needed to confirm these results, the real-world data are compelling and could reshape how gastroenterologists approach treatment for UC patients already on GLP-1 therapy.
